Medscape is available in 5 Language Editions – Choose your Edition here.


Membranoproliferative Glomerulonephritis Treatment & Management

  • Author: Pranay Kathuria, MD; Chief Editor: Vecihi Batuman, MD, FACP, FASN  more...
Updated: Jun 23, 2016

Approach Considerations

Membranoproliferative glomerulonephritis (MPGN) is a rare glomerulonephritis with a protracted natural history, which makes studies on treatment logistically difficult to conduct. No serologic markers are available to assess disease activity. Most studies are confined to MPGN type I and have a relatively short-term follow-up period; furthermore, hepatitis C virus (HCV) is now known to be an important cause of many cases that were previously thought to be idiopathic MPGN,[20, 21, 23, 24, 25, 26] making older treatment results difficult to interpret.

Only a handful of randomized controlled trials have been published with sufficient power to determine the benefits of therapy for MPGN. The use of variable end points (eg, reduction in proteinuria, renal function measured using variable techniques) further confounds the data.

Thus, the optimal treatment of idiopathic MPGN is not clearly defined. Specific therapies should be reserved for patients with MPGN who have one or more of the following indications:

  • Proteinuria exceeding 3 g/d
  • Active interstitial or glomerular disease (crescents) on biopsy
  • Impaired renal function at presentation
  • A progressive decline in renal function

Consultations with nephrology, hepatology (if hepatitis virus B– or HCV-associated MPGN), and nutrition specialists may be helpful in managing patients with this rare disease.


Treatment of Idiopathic MPGN

General measures

The Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guidelines[27] recommend treating patients with proteinuria of greater than 30 mg/24 hours with blood pressure–lowering drugs to achieve a blood pressure consistently less than 130 mm Hg systolic and 80 mm Hg diastolic. The guidelines also recommend using an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin receptor blocker (ARB) when the proteinuria exceeds 30 mg in 24 hours, for patients in whom treatment with blood pressure–lowering drugs is indicated. Normotensive patients with proteinuria should also be treated with angiotensin inhibition.

The combination of ACE inhibitors and ARBs may result in additive antiproteinuric activity, although there is conflicting evidence as to the risk-benefit ratio of this strategy, especially if the glomerular filtration rate (GFR) is significantly reduced.[27] Nondihydropyridine calcium channel blockers such as verapamil and diltiazem may also have antiproteinuric effects.

Diuretics are usually needed to control hypertension and manage edema. Thiazide diuretics suffice for many patients. Loop diuretics are indicated for more refractory edema with renal insufficiency. A combination of diuretics acting at different sites in the tubule may be needed in some patients. Potassium-sparing diuretics may be used concomitantly to prevent hypokalemia. Patients with severe and refractory edema and those with hypovolemia and orthostatic hypotension may respond to salt-free albumin infusions.

Lipids must be controlled according to the National Cholesterol Education Program (NCEP) guidelines, although several nephrologists recommend low-density lipoprotein (LDL) cholesterol levels to be maintained below 70 mg/dL.

Patients should be given the pneumococcal vaccine and yearly influenza vaccine.

Specific measures

Approaches to treatment of idiopathic membranoproliferative glomerulonephritis (MPGN) have included immunosuppression, inhibiting platelet-induced injury with aspirin and dipyridamole, minimizing glomerular fibrin deposition with anticoagulants, and use of steroidal and nonsteroidal anti-inflammatory agents. Anticoagulant and nonsteroidal therapies have been found to have minimal beneficial effects and are associated with severe adverse effects.

Immunosuppression may be indicated for patients with nephrotic syndrome, progressive decline in kidney function, or very active inflammation (crescents) on the biopsy. Patients with normal GFR and non-nephrotic proteinuria should be managed conservatively and followed closely.


Children with idiopathic MPGN type I who have nephrotic-range proteinuria, interstitial disease, or renal insufficiency may benefit from corticosteroid therapy. No systemic evaluation of corticosteroid therapy has occurred in adults.

Benefits in children include stabilization of the renal function, slowing of the decline in GFR, and a decrease in proteinuria. These therapies are associated with multiple complications, including hypertension and seizures in children. Because active inflammation is more likely to be present early in the disease, prompt initiation of therapy may provide better outcomes.

In the International Study of Kidney Disease in Children, investigators suggested the outcome of children with MPGN may be improved with long-term use of prednisone.[28] Alternate-day prednisone was administered for a mean of 130 months; at the end of the study period, approximately 61% of the treatment group had stable renal function relative to 12% of the control group.[28]

The group at Cincinnati has also shown benefit of prolonged alternate-day steroid regimens.[29] Renal survival rates improved, and findings on repeat kidney biopsy at 2 years demonstrated an increase in capillaries with open lumina and a decrease in mesangial matrix and cellularity; however, an increase in glomerular sclerosis and tubular atrophy occurred.[29] The same group reported that patients with MPGN type III respond poorly to steroids.[17] Several other studies also documented the benefit of steroid therapy in types I and II MPGN.[30]

Antiplatelet therapy

Antiplatelet therapies benefit adults with MPGN. Probable mechanisms that underlie the therapeutic benefits of aspirin include inhibition of platelet aggregation, mesangial proliferation, and alteration of renal hemodynamics. Dipyridamole may enhance the effects of aspirin.

In one randomized controlled study, the use of antiplatelet agents administered over 1 year reduced the incidence of renal failure at 3-5 years, but the renal survival rate was no different at 10 years.[31] In another study of 18 patients with biopsy-proven MPGN (15 type I, 3 type II) and nephrotic syndrome and moderately reduced kidney function, dipyridamole and aspirin caused a significant reduction in proteinuria at 3 years, with no impact on renal function.[32] Reduction in proteinuria to a non-nephrotic range was documented in a group of 14 patients treated with this combination for 2 years by Harmakayaet al.[33] One small uncontrolled study of MPGN type I in children found improved outcome and attenuated inflammation on biopsy with the administration of a combination of prednisolone and dipyridamole.[30]


Cyclophosphamide therapy is generally recommended for rapidly progressive kidney failure (crescentic glomerulonephritis) in conjunction with intravenous steroids.

In a 10-month study of 19 pediatric and adult patients with MPGN, therapy was induced with pulse methylprednisone and cyclophosphamide and maintained with cyclophosphamide and every-other-day prednisone. Steroids were tapered in the third phase of the study. Lastly, cyclophosphamide was stopped and prednisone gradually withdrawn. Fifteen patients remitted, 3 improved, and 1 progressed. There were 8 relapses in 6 patients: 4 in 3 patients were treated with repeat cycles and remitted completely. Four patients who had relapsed after 4, 8, 11, and 13 years of remission refused retreatment and progressed rapidly to ESRD.[34]

A study by Cattran et al found no benefit with a treatment regimen of cyclophosphamide, warfarin, and dipyridamole in MPGN types I and II with a GFR of less than 80 mL/min and/or proteinuria greater than 2 g/day.[35]

Mycophenolate mofetil

Data on the use of mycophenolate in MPGN are very limited. An observational study reported that 5 patients with idiopathic MPGN had significant reduction in proteinuria over an 18-month period when they were treated with oral prednisolone and mycophenolate mofetil relative to a control group of 6 patients who did not receive immunosuppression.[36] No significant change occurred in serum creatinine or creatinine clearance in the treatment group; however, in the control group, serum creatinine and creatinine clearance deteriorated significantly.[36]

Calcineurin inhibitors

A small case series demonstrated that cyclosporine was effective in the treatment of MPGN that had failed alternative treatments. Eighteen patients were treated with cyclosporine plus low-dose prednisone and were followed for an average 108 weeks. Partial or complete remission of proteinuria occurred in 94% of the patients (P <0.01). Relapse occurred in one (14.2%) of the remitters after discontinuation of the drug.[37]


Anecdotal reports have demonstrated the efficacy or rituximab in treating MPGN secondary to chronic lymphocytic leukemia.[38, 39] Rituximab has also been shown to be effective in patients with MPGN related to a monoclonal gammopathy.[40]

In an open label trial with rituximab, six patients with MPGN type I were treated with rituximab 1000 mg on days 1 and 15 and followed for 1 year. Proteinuria fell in all patients, at all time points, after rituximab administration. Renal function did not change.[41]

Other treatment options

New treatments on the horizon include eculizumab, an anti-C5 antibody, to decrease C5-mediated glomerular damage. Case reports have supported the use of eculizumab in refractory MPGN secondary to complement dysregulation. However, clinical trials are still underway to establish its use in MPGN and C3 glomerulonephritis.

Other potential treatments of MPGN type II include plasma infusion/plasmapheresis and reducing C3NeF (nephritic factor of the amplification loop). Plasma infusion or plasmapheresis with plasma exchange may provide functionally intact factor H in patients with defined pathologic mutation of the factor H gene.


Secondary MPGN

Every patient with membranoproliferative glomerulonephritis (MPGN) must be carefully evaluated for a secondary cause of the disease. An excellent history, histopathologic findings, and serologies may help identify the underlying cause.

Appropriate treatment of infections such as endocarditis or infected ventriculoatrial shunts may induce remissions. Antiviral therapy is indicated for hepatitis B and C. Aggressive immunosuppression and plasmapheresis should be reserved for patients with severe acute MPGN and/or vasculitis with hepatitis C. For patients with lupus and other rheumatologic conditions, offer treatment based on principles of care for those diseases.


Diet and Activity

Dietary considerations include sodium, protein, and lipid intake.

Dietary sodium needs to be restricted to 3 to 4g/d. These measures, along with the judicious use of diuretics, can be very useful in managing hypertension and edema.

Ensure that patients with normal renal function receive a protein intake of approximately 1 g/kg/d, plus the amount lost in urine. Confirm that the protein is of high biologic value. Higher protein intake does not improve nutrition, because protein catabolism increases proportionally; however, once renal insufficiency develops, recommend moderate protein restriction (eg, 0.65-0.80 g/kg/d, plus urinary losses).

Recommend a low-cholesterol healthy-heart diet to patients, because hyperlipidemia is common with nephrotic proteinuria.

No restriction of activity is recommended, unless the patient has uncontrolled severe hypertension. Note that diuretics are most effective when the patient is supine. In patients with resistant edema, lying down after taking diuretics may increase their efficacy.


Pregnant Patients

Underlying renal diseases, including membranoproliferative glomerulonephritis (MPGN), increase the risk of fetal loss, intrauterine growth restriction, and prematurity. Patients with hypertension, renal insufficiency, and nephrotic syndrome have increased risks for a more unfavorable fetal outcome. Preeclampsia develops in 20-40% of patients with underlying renal disease. The development of preeclampsia increases the risks of fetal wastage.

Patients with MPGN are more likely than those with most other glomerular diseases to develop deterioration of renal function, increasing proteinuria, or worsening of hypertension during pregnancy. The risk for adverse outcomes depends on the patient's severity of hypertension, 24-hour proteinuria, and the level of renal function before pregnancy.

Better fetal outcome is reported in patients with MPGN type II (dense deposit disease) who have normal renal function, as compared with patients with MPGN type I.[42]

Close monitoring of the patient by a high-risk obstetrician and a nephrologist is essential during pregnancy.


Long-Term Monitoring

Patients should be followed at regular intervals. The frequency of visits should be dictated by the level of kidney function, level of proteinuria, and nature of intervention prescribed. Kidney function, proteinuria and clearances, lipid profiles, and serum albumin should be followed during these visits. The urine albumin–to–creatinine ratio may be used as a rough guide to 24-hour urinary albumin excretion. The nutritional status should be assessed using the subjective global assessment (SGA) scale.


Patient Education

Ensure that patients with progressive azotemia receive timely education regarding renal replacement options.[43] In addition, recommend that patients have frequent follow-up visits with a dietitian, which are essential to ensuring patient diet compliance.

For patient information, see Chronic Kidney Disease, and Kidney Transplant. Further information is available at the Mayo Clinic's Kidney Transplant Web pages.

Contributor Information and Disclosures

Pranay Kathuria, MD FACP, FASN, FNKF, Professor of Medicine, Director, Division of Nephrology and Hypertension, University of Oklahoma School of Community Medicine

Pranay Kathuria, MD is a member of the following medical societies: American College of Physicians-American Society of Internal Medicine, American Heart Association, American Society of Hypertension, American Society of Nephrology, National Kidney Foundation

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Ajay K Singh, MB, MRCP, MBA Associate Professor of Medicine, Harvard Medical School; Director of Dialysis, Renal Division, Brigham and Women's Hospital; Director, Brigham/Falkner Dialysis Unit, Faulkner Hospital

Disclosure: Nothing to disclose.

Chief Editor

Vecihi Batuman, MD, FACP, FASN Huberwald Professor of Medicine, Section of Nephrology-Hypertension, Tulane University School of Medicine; Chief, Renal Section, Southeast Louisiana Veterans Health Care System

Vecihi Batuman, MD, FACP, FASN is a member of the following medical societies: American College of Physicians, American Society of Hypertension, American Society of Nephrology, International Society of Nephrology

Disclosure: Nothing to disclose.

Additional Contributors

F John Gennari, MD Associate Chair for Academic Affairs, Robert F and Genevieve B Patrick Professor, Department of Medicine, University of Vermont College of Medicine

F John Gennari, MD is a member of the following medical societies: Alpha Omega Alpha, American College of Physicians-American Society of Internal Medicine, American Federation for Medical Research, American Heart Association, American Physiological Society, American Society for Clinical Investigation, American Society of Nephrology, International Society of Nephrology

Disclosure: Nothing to disclose.


The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous authors Martin Senitko, MD, and Sandeep Singh, MD, to the development and writing of the source article.

  1. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis--a new look at an old entity. N Engl J Med. 2012 Mar 22. 366(12):1119-31. [Medline].

  2. Lorenz EC, Sethi S, Leung N, Dispenzieri A, Fervenza FC, Cosio FG. Recurrent membranoproliferative glomerulonephritis after kidney transplantation. Kidney Int. 2010 Apr. 77(8):721-8. [Medline].

  3. Appel GB. Membranoprolferative glomerulonephritis - mechanisms and treatment. Contrib Nephrol. 2013. 181:163-74. [Medline].

  4. Smith KD, Alpers CE. Pathogenic mechanisms in membranoproliferative glomerulonephritis. Curr Opin Nephrol Hypertens. 2005 Jul. 14(4):396-403. [Medline].

  5. Varade WS, Forristal J, West CD. Patterns of complement activation in idiopathic membranoproliferative glomerulonephritis, types I, II, and III. Am J Kidney Dis. 1990 Sep. 16(3):196-206. [Medline].

  6. Levy Y, George J, Yona E, et al. Partial lipodystrophy, mesangiocapillary glomerulonephritis, and complement dysregulation. An autoimmune phenomenon. Immunol Res. 1998 Aug. 18(1):55-60. [Medline].

  7. Walker PD. Dense deposit disease: new insights. Curr Opin Nephrol Hypertens. 2007 May. 16(3):204-12. [Medline].

  8. Licht C, Schlötzer-Schrehardt U, Kirschfink M, et al. MPGN II--genetically determined by defective complement regulation?. Pediatr Nephrol. 2007 Jan. 22(1):2-9. [Medline].

  9. Sethi S, Fervenza FC, Zhang Y, Zand L, Vrana JA, Nasr SH. C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up. Kidney Int. 2012 Aug. 82(4):465-73. [Medline].

  10. Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012 Mar. 81(5):434-41. [Medline].

  11. Nargund P, Kambham N, Mehta K, Lafayette RA. Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. Clin Nephrol. 2015 Dec. 84 (12):323-30. [Medline].

  12. Neary JJ, Conlon PJ, Croke D, et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol. 2002 Aug. 13(8):2052-7. [Medline].

  13. Izzedine H, Sene D, Cacoub P, et al. Kidney diseases in HIV/HCV-co-infected patients. AIDS. 2009 Jun 19. 23(10):1219-26. [Medline].

  14. Hiramatsu R, Hoshino J, Suwabe T, Sumida K, Hasegawa E, Yamanouchi M, et al. Membranoproliferative glomerulonephritis and circulating cryoglobulins. Clin Exp Nephrol. 2013 May 31. [Medline].

  15. Tang SC, Lai KN. Hepatitis C virus-associated glomerulonephritis. Contrib Nephrol. 2013. 181:194-206. [Medline].

  16. Cansick JC, Lennon R, Cummins CL, et al. Prognosis, treatment and outcome of childhood mesangiocapillary (membranoproliferative) glomerulonephritis. Nephrol Dial Transplant. 2004 Nov. 19(11):2769-77. [Medline].

  17. Cameron JS, Turner DR, Heaton J, et al. Idiopathic mesangiocapillary glomerulonephritis. Comparison of types I and II in children and adults and long-term prognosis. Am J Med. 1983 Feb. 74(2):175-92. [Medline].

  18. O'Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC. Differences in initial treatment modality for end-stage renal disease among glomerulonephritis subtypes in the USA. Nephrol Dial Transplant. 2015 Nov 25. [Medline].

  19. Iitaka K, Moriya S, Nakamura S, et al. Long-term follow-up of type III membranoproliferative glomerulonephritis in children. Pediatr Nephrol. 2002 May. 17(5):373-8. [Medline].

  20. Anders D, Agricola B, Sippel M, et al. Basement membrane changes in membranoproliferative glomerulonephritis. II. Characterization of a third type by silver impregnation of ultra thin sections. Virchows Arch A Pathol Anat Histol. 1977 Oct 27. 376(1):1-19. [Medline].

  21. Braun MC, West CD, Strife CF. Differences between membranoproliferative glomerulonephritis types I and III in long-term response to an alternate-day prednisone regimen. Am J Kidney Dis. 1999 Dec. 34(6):1022-32. [Medline].

  22. Kawasaki Y, Kanno S, Ono A, Suzuki Y, Ohara S, Sato M, et al. Differences in clinical findings, pathology, and outcomes between C3 glomerulonephritis and membranoproliferative glomerulonephritis. Pediatr Nephrol. 2016 Jul. 31 (7):1091-9. [Medline].

  23. Masai R, Wakui H, Komatsuda A, et al. Characteristics of proliferative glomerulo-nephritis with monoclonal IgG deposits associated with membranoproliferative features. Clin Nephrol. 2009 Jul. 72(1):46-54. [Medline].

  24. Nasr SH, Satoskar A, Markowitz GS, et al. Proliferative glomerulonephritis with monoclonal IgG deposits. J Am Soc Nephrol. 2009 Sep. 20(9):2055-64. [Medline]. [Full Text].

  25. D'Amico G, Fornasieri A. Cryoglobulinemic glomerulonephritis: a membranoproliferative glomerulonephritis induced by hepatitis C virus. Am J Kidney Dis. 1995 Mar. 25(3):361-9. [Medline].

  26. Daghestani L, Pomeroy C. Renal manifestations of hepatitis C infection. Am J Med. 1999 Mar. 106(3):347-54. [Medline].

  27. Kidney Disease Improving Global Outcomes. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Available at Accessed: May 28, 2013.

  28. Arikan H, Koc M, Cakalagaoglu F, et al. Histopathological changes and tumour necrosis factor-alpha, transforming growth factor-beta and tenascin expression in patients with primary type I membranoproliferative glomerulonephritis in remission. Nephrology (Carlton). 2009 Apr. 14(2):219-26. [Medline].

  29. Jungers P, Chauveau D. Pregnancy in renal disease. Kidney Int. 1997 Oct. 52(4):871-85. [Medline].

  30. Jones G, Juszczak M, Kingdon E, et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant. 2004 Dec. 19(12):3160-4. [Medline].

  31. Smith RJ, Alexander J, Barlow PN, et al. New approaches to the treatment of dense deposit disease. J Am Soc Nephrol. 2007 Sep. 18(9):2447-56. [Medline].

  32. Tarshish P, Bernstein J, Tobin JN, et al. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone--a report of the International Study of Kidney Disease in Children. Pediatr Nephrol. 1992 Mar. 6(2):123-30. [Medline].

  33. Harmankaya O, Basturk T, Ozturk Y, Karabiber N, Obek A. Effect of acetylsalicylic acid and dipyridamole in primary membranoproliferative glomerulonephritis type I. Int Urol Nephrol. 2001. 33(3):583-7. [Medline].

  34. Faedda R, Satta A, Tanda F, Pirisi M, Bartoli E. Immunosuppressive treatment of membranoproliferative glomerulonephritis. Nephron. 1994. 67(1):59-65. [Medline].

  35. Cattran DC, Cardella CJ, Roscoe JM, et al. Results of a controlled drug trial in membranoproliferative glomerulonephritis. Kidney Int. 1985 Feb. 27(2):436-41. [Medline].

  36. Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant. 2003 Aug. 18(8):1573-80. [Medline].

  37. Bagheri N, Nemati E, Rahbar K, Nobakht A, Einollahi B, Taheri S. Cyclosporine in the treatment of membranoproliferative glomerulonephritis. Arch Iran Med. 2008 Jan. 11(1):26-9. [Medline].

  38. Bhat P, Weiss S, Appel GB, Radhakrishnan J. Rituximab treatment of dysproteinemias affecting the kidney: a review of three cases. Am J Kidney Dis. 2007 Oct. 50(4):641-4. [Medline].

  39. Vilayur E, Trevillian P, Walsh M. Monoclonal gammopathy and glomerulopathy associated with chronic lymphocytic leukemia. Nat Clin Pract Nephrol. 2009 Jan. 5(1):54-8. [Medline].

  40. Guiard E, Karras A, Plaisier E, Duong Van Huyen JP, Fakhouri F, Rougier JP. Patterns of noncryoglobulinemic glomerulonephritis with monoclonal Ig deposits: correlation with IgG subclass and response to rituximab. Clin J Am Soc Nephrol. 2011 Jul. 6(7):1609-16. [Medline].

  41. Dillon JJ, Hladunewich M, Haley WE, Reich HN, Cattran DC, Fervenza FC. Rituximab therapy for Type I membranoproliferative glomerulonephritis. Clin Nephrol. 2012 Apr. 77(4):290-5. [Medline].

  42. Misiani R, Bellavita P, Fenili D, et al. Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med. 1994 Mar 17. 330(11):751-6. [Medline].

  43. Pippias M, Stel VS, Aresté-Fosalba N, Couchoud C, Fernandez-Fresnedo G, Finne P, et al. Long-term Kidney Transplant Outcomes in Primary Glomerulonephritis: Analysis From the ERA-EDTA Registry. Transplantation. 2015 Nov 19. [Medline].

  44. Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol. 2005 May. 16(5):1392-403. [Medline].

  45. Garini G, Allegri L, Vaglio A, et al. Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies. Ann Ital Med Int. 2005 Apr-Jun. 20(2):71-80. [Medline].

  46. Hanko JB, Mullan RN, O'Rourke DM, et al. The changing pattern of adult primary glomerular disease. Nephrol Dial Transplant. 2009 Oct. 24(10):3050-4. [Medline].

  47. Javaugue V, Karras A, Glowacki F, McGregor B, Lacombe C, Goujon JM, et al. Long-term Kidney Disease Outcomes in Fibrillary Glomerulonephritis: A Case Series of 27 Patients. Am J Kidney Dis. 2013 Jun 4. [Medline].

  48. Skerka C, Licht C, Mengel M, et al. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles. Mol Immunol. 2009 Sep. 46(14):2801-7. [Medline].

Membranoproliferative glomerulonephritis (MPGN) type I. Glomerulus with lobular accentuation from increased mesangial cellularity. A segmental increase occurs in the mesangial matrix, and the peripheral capillary walls are thickened (hematoxylin and eosin stained section; original magnification × 250). Courtesy of John A. Minielly, MD.
Membranoproliferative glomerulonephritis (MPGN) type I. Electron microscopy of prominent, glomerular, subendothelial, immune-type electron deposits (original magnification × 11,400). Courtesy of John A. Minielly, MD.
Membranoproliferative glomerulonephritis (MPGN) type I. Glomerulus with mesangial interposition producing a double contouring of basement membranes, which, in areas, appear to surround subendothelial deposits (Jones silver methenamine–stained section; original magnification × 400). Courtesy of John A. Minielly, MD.
Membranoproliferative glomerulonephritis (MPGN) type II. Electron microscopy of glomerular basement membrane, intramembranous, somewhat linear, electron dense deposit (ie, dense deposit disease; original magnification × 11,400). Courtesy of John A. Minielly, MD.
Membranoproliferative glomerulonephritis (MPGN) type I. Immunofluorescent stained section. Intense, peripheral, glomerular, capillary loop deposition of immunoglobulin G (IgG) in an interrupted linear pattern corresponding to extensive subendothelial immune deposits (original magnification × 400). Courtesy of John A. Minielly, MD.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.